Neurological Biomarkers Market Size, Statistics Report 2034

Neurological Biomarkers Market – By Product Type, By Disease Type, By End Use, Global Forecast, 2025 to 2034

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology and Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definition

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600&nbsp;synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing prevalence of neurological disorders

3.2.1.2&nbsp;&nbsp;&nbsp; Advancement in biomarker research

3.2.1.3&nbsp;&nbsp;&nbsp; Adoption of personalized medicine

3.2.1.4&nbsp;&nbsp;&nbsp; Rising awareness among patients and healthcare providers of neurological disorders

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High cost of biomarker testing

3.2.2.2&nbsp;&nbsp;&nbsp; Lack of standardization

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Future market trends

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2024

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Product Type, 2021 &ndash; 2034 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Proteomic biomarkers

5.3&nbsp;&nbsp;&nbsp; Genomic biomarkers

5.4&nbsp;&nbsp;&nbsp; Metabolomic biomarkers

5.5&nbsp;&nbsp;&nbsp; Imaging

5.6&nbsp;&nbsp;&nbsp; Other biomarker types

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Disease Type, 2021 &ndash; 2034 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Alzheimer&rsquo;s disease

6.3&nbsp;&nbsp;&nbsp; Parkinson&rsquo;s disease

6.4&nbsp;&nbsp;&nbsp; Autism spectrum disorders

6.5&nbsp;&nbsp;&nbsp; Epilepsy

6.6&nbsp;&nbsp;&nbsp; Other diseases

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End Use, 2021 &ndash; 2034 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Hospitals and clinics

7.3&nbsp;&nbsp;&nbsp; Research laboratories

7.4&nbsp;&nbsp;&nbsp; Biopharmaceutical companies

7.5&nbsp;&nbsp;&nbsp; Other end users

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2034 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Netherlands

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; China

8.4.2&nbsp;&nbsp;&nbsp; India

8.4.3&nbsp;&nbsp;&nbsp; Japan

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; South Korea

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Argentina

8.6&nbsp;&nbsp;&nbsp; Middle East and Africa

8.6.1&nbsp;&nbsp;&nbsp; South Africa

8.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp; UAE

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; Abbott Laboratories

9.2&nbsp;&nbsp;&nbsp; ACOBIOM

9.3&nbsp;&nbsp;&nbsp; Alseres Pharmaceuticals

9.4&nbsp;&nbsp;&nbsp; Banyan Biomarkers

9.5&nbsp;&nbsp;&nbsp; Bio-Rad Laboratories

9.6&nbsp;&nbsp;&nbsp; DiaGenic ASA

9.7&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson Services

9.8&nbsp;&nbsp;&nbsp; Merck KGaA

9.9&nbsp;&nbsp;&nbsp; QIAGEN

9.10&nbsp;&nbsp;&nbsp; Quanterix

9.11&nbsp;&nbsp;&nbsp; Rules-Based Medicine

9.12&nbsp;&nbsp;&nbsp; Thermo Fisher Scientific 
&nbsp;

Neurological Biomarkers Market

Get a free sample of this report